VisionGate Announces an Exclusive Global License, Manufacturing and Supply Agreement for Iloprost, VisionGate’s Phase 2 Oral Lung Cancer Interception Drug
August 22, 2019 08:00 ET
|
VisionGate, Inc.
Seattle, WA, Aug. 22, 2019 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, announces that it has finalized an exclusive worldwide license...
VisionGate Announces Lung Cancer Prevention Trial Progress
January 29, 2019 11:32 ET
|
VisionGate, Inc.
Seattle, WA, Jan. 29, 2019 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, announces that it has selected PCI Pharma Services to provide...
VisionGate, Inc. Appoints R. John Glasspool as Chief Operating and Strategy Officer and member of the Board of Directors
October 11, 2018 10:06 ET
|
VisionGate, Inc.
Seattle, WA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- VisionGate, Inc., an integrated, clinical-stage, oncology pharmaceutical and diagnostics company, is pleased to announce the appointment of R. John...
VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy
September 24, 2018 06:00 ET
|
VisionGate, Inc.
Seattle, WA, Sept. 24, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International...
VisionGate Announces New Appointment to the Board of Directors
June 14, 2018 14:06 ET
|
VisionGate, Inc.
SEATTLE, WA, June 14, 2018 (GLOBE NEWSWIRE) -- VisionGate is pleased to announce the appointment of Dr. James S. (Jim) Burns to the Board of Directors, expanding the depth of biotech leadership and...
VisionGate, Inc. Appoints Randal Buness as Chief Financial Officer
April 17, 2018 18:34 ET
|
VisionGate, Inc.
SEATTLE, WA, April 17, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce the appointment of Randal Buness, CPA, MBA as...
VisionGate’s Cell-CT™ 3D Cellular Imaging Platform Detects the Presence of Cancer-Associated Cells (CACs) that have undergone Malignancy Associated Change (MAC)
April 16, 2018 09:23 ET
|
VisionGate, Inc.
SEATTLE, WA, April 16, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, today presented a breakthrough research study demonstrated its Cell-CT™...
VisionGate Lung Cancer 3D Cellular Imaging Research to be Featured as a Late-Breaking Abstract at the AACR Annual Meeting 2018
April 12, 2018 13:46 ET
|
VisionGate, Inc.
SEATTLE, WA, April 12, 2018 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce that new lung cancer 3D cellular imaging...
VisionGate is Leveraging the Cell-CT™ Platform to Expand Cancer Diagnostics Services, Biopharmaceutical Services and Cancer Prevention Medicines
April 05, 2018 14:03 ET
|
VisionGate, Inc.
SEATTLE, WA, April 05, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce today the advancement of its breakthrough...
VisionGate Announces Two New Appointments to the Board of Directors
April 04, 2018 16:21 ET
|
VisionGate, Inc.
SEATTLE, WA, April 04, 2018 (GLOBE NEWSWIRE) -- VisionGate is pleased to announce the appointment of two new members to the Board of Directors, significantly expanding the depth of biotech...